1. Home
  2. CKPT vs RBB Comparison

CKPT vs RBB Comparison

Compare CKPT & RBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CKPT
  • RBB
  • Stock Information
  • Founded
  • CKPT 2014
  • RBB 2008
  • Country
  • CKPT United States
  • RBB United States
  • Employees
  • CKPT N/A
  • RBB N/A
  • Industry
  • CKPT Biotechnology: Pharmaceutical Preparations
  • RBB Major Banks
  • Sector
  • CKPT Health Care
  • RBB Finance
  • Exchange
  • CKPT Nasdaq
  • RBB Nasdaq
  • Market Cap
  • CKPT 335.9M
  • RBB 292.5M
  • IPO Year
  • CKPT 2017
  • RBB 2017
  • Fundamental
  • Price
  • CKPT $4.04
  • RBB $15.08
  • Analyst Decision
  • CKPT Buy
  • RBB Hold
  • Analyst Count
  • CKPT 3
  • RBB 4
  • Target Price
  • CKPT $4.33
  • RBB $21.25
  • AVG Volume (30 Days)
  • CKPT 1.7M
  • RBB 36.4K
  • Earning Date
  • CKPT 05-09-2025
  • RBB 04-28-2025
  • Dividend Yield
  • CKPT N/A
  • RBB 4.24%
  • EPS Growth
  • CKPT N/A
  • RBB N/A
  • EPS
  • CKPT N/A
  • RBB 1.47
  • Revenue
  • CKPT $41,000.00
  • RBB $104,842,000.00
  • Revenue This Year
  • CKPT $102,182.93
  • RBB $14.95
  • Revenue Next Year
  • CKPT $351.71
  • RBB $7.77
  • P/E Ratio
  • CKPT N/A
  • RBB $10.26
  • Revenue Growth
  • CKPT N/A
  • RBB N/A
  • 52 Week Low
  • CKPT $1.38
  • RBB $14.49
  • 52 Week High
  • CKPT $4.50
  • RBB $25.30
  • Technical
  • Relative Strength Index (RSI)
  • CKPT 63.60
  • RBB 33.18
  • Support Level
  • CKPT $3.94
  • RBB $14.62
  • Resistance Level
  • CKPT $4.06
  • RBB $15.44
  • Average True Range (ATR)
  • CKPT 0.05
  • RBB 0.73
  • MACD
  • CKPT -0.03
  • RBB -0.03
  • Stochastic Oscillator
  • CKPT 83.33
  • RBB 26.82

About CKPT Checkpoint Therapeutics Inc.

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

About RBB RBB Bancorp

RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.

Share on Social Networks: